A Phase III Multicenter, Observer-Blinded, Randomized, Active Controlled, Immune Non-inferiority and Safety Study of Vi-DT Vaccine Compared to Typbar TCV in Healthy 6 Months-45 Years Aged Nepalese Participants.
Latest Information Update: 03 Mar 2024
At a glance
- Drugs Typhoid vaccine Vi DT conjugate International Vaccine Institute/Incepta/SK Bioscience/PT Biofarma (Primary) ; Typhoid vaccine Vi conjugate
- Indications Typhoid
- Focus Pharmacodynamics; Registrational
Most Recent Events
- 23 Feb 2024 According to a SK Bioscience media release, the SKYTyphoid has received an export license from the Korean Ministry of Food and Drug Safety in 2022, based on the results of this global clinical study. The company has obtained prequalification (PQ) certification from the World Health Organization (WHO) for, SKYTyphoid. The WHO PQ system evaluates the manufacturing process, quality, and clinical trial results of a vaccine according to strict criteria to certify its safety and efficacy.
- 01 Apr 2022 Results published in The Lancet Infectious Diseases
- 26 Nov 2019 Status changed from not yet recruiting to recruiting.